Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

This was the stock's second consecutive day of losses.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

【ビジネスワイヤ】米女性化粧品ブランドのメアリー・ケイは、オハイオ州コロンバスで開催の高校生向けグローバルＳＴＥＭコンペティション「リジェネロン国際学生科学技術フェア（Ｒｅｇｅｎｅｒｏｎ・ＩＳＥＦ）」に特別賞授与団体として参加したことを発表した。同フェアは、６０カ国以上から約２０００人が参加し、総額９００万ドルを超える賞金や奨学金が与えられるとともに、ＳＴＥ ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

The stock's fall snapped a two-day winning streak.